Detection of peripheral blood HBV-LHBs transactivation function and its relationship with anti-viral efficacy
Xu, A.-f.; Chen, G.; Wang, M.-c.; Sui, D.-m.; Zhu, X.-y.; Shi, J.-p.; Zhang, Y.-l.; Lou, G.-q.
Zhonghua Shi Yan he Lin Chuang Bing du Xue Za Zhi 23(5): 375-377
2009
ISSN/ISBN: 1003-9279 PMID: 20387491 Document Number: 634714
Explore the serum of patients with CHB of HBV large envelope protein (HBV-LHBs) trans-activation function and antiviral therapy effect relationship. 60 cases of anti-viral treatment of patients with chronic hepatitis B to take every 3 months HBVDNA, HBV-LHBs, as well as detection of hepatitis B immune markers to observe the changes in indexes. Income group 60 cases of anti-virus group HBVDNA with HBV-LHBs have a higher detection rate of the consistency of the results found no statistical significance (P > 0.05), HBV-LHBs-positive rate and positive rate of HBeAg differences (chi2 = 4.08, P < 0.05). After 24 months of antiviral therapy HBV-LHBs expression always HBVDNA in 29 cases of which occurred 24 months after the negative reaction of the 20 cases, continuous positive were seven cases of non-negative. 60 cases of patients 24 months found no HBsAg seroconversion, four cases of emergence of HBeAg seroconversion. (1) detection of serum HBV-LHBs to reflect the hepatitis B virus replication with HBVDNA good correlation. (2) anti-viral treatment of dynamic observation of the process of HBV-LHBs expression can predict the effectiveness of anti-viral therapy.